**3. New antifungals**

The resistance of *C. albicans* and other pathogenic fungi to current antifungal agents has established the need to find new antifungal targets with a novel mechanism of action. Resistant strains are increasing in number for some classes of antifungal agents, particularly for azoles and echinocandins [53]. Consequently, it is necessary to face the challenge of successfully managing fungal infections. To achieve this, one of the main points is the continuation of the development of new antifungal drugs [54]. The main issues faced by the development of new drugs are: 1) they must have a broad spectrum against emerging filamentous yeasts and fungi and 2) they must have a more efficient fungicidal activity to eliminate pathogens quickly and totally [55–59]. Besides, invasive candidiasis occurs in very frail patients who do not tolerate much organ toxicity, since such patients are often taking many other therapeutic agents, so drug–drug interactions must be carefully considered [60].
